Skip to main content
KBS_Icon_questionmark link-ico

Process Development and Process Innovation

The London Hub Process Innovation Working Groups, formed by the leading experts from UCL, RF and KCL, are collaborating closely to deliver on a substantial programme of manufacturing process innovation, aiming to address some of the key manufacturing challenges faced by the field.

The goal is to develop new platforms and processes to keep the UK Gene Therapy Research Infrastructure at the cutting edge, to increase yields, reduce costs, and speed up the transition into first-in-human studies, while ensuring that processes are suitable for scale-up to later stage/larger-scale manufacturing. The London Hub will work closely with commercial providers of downstream processing solutions to apply their technology where appropriate.

The structured innovation programme will include the following activities:

  • KCL Team led by Prof Robin Ali is focusing on process improvements, including transfection protocols and downstream steps of production to increase the yields of the LV and AAV vectors.
  • RF Team led by Prof Mark Lowdell & Prof Martin Pule is developing the suspension technology, to deliver high yields and scalability of the LV production process.
  • UCL team led by prof Martin Pule is working on highly innovative technologies to develop effective stable-producer cell lines and generate affinity-tagged LV vectors.

The Process Development and Process Innovation team will support clients by actioning the following activities:

  • Optimisation of batch size and yield
  • Fostering of high-quality skills and expertise
About the London Innovation Hub for Gene Therapies

About us

More details about the London Innovation Hub for Gene Therapies

Our People

Our People

Details of the people involved at the London Innovation Hub for Gene Therapies



Manufacturing at the London Innovation Hub for Gene Therapies